Title: ARPE-19 as a platform cell line for encapsulated cell-based delivery
United States Patent: 6,361,771Inventors: Tao; Weng (Lincon, RI); Rein; David H. (Cambridge, MA); Dean; Brenda J. (Cumberland, RI); Stabila; Paul F. (Coventry, RI); Goddard; Moses B.I. (Tiverton, RI)
Assignee: Neurotech S.A. (Evry, FR)Appl. No.: 543119
Filed: April 5, 2000
ARPE-19 cells were evaluated as a platform cell line for encapsulated and un-encapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; has a long life span; is of human origin; has good in vivo device viability; delivers efficacious quantity of growth factor; triggers no or low level host immune reaction, and is non-tumorigenic.
SUMMARY OF THE INVENTION
The ARPE-19 cell line is a superior platform cell line for encapsulated
cell based delivery technology and is also useful for unencapsulated cell
based delivery technology. The ARPE-19 cell line is hardy (i.e., the cell
line is viable under stringent conditions, such as implantation in the
central nervous system or the intra-ocular environment). ARPE-19 cells can
be genetically modified to secrete a substance of therapeutic interest.
ARPE-19 cells have a relatively long life span. ARPE-19 cells are of human
origin. Furthermore, encapsulated ARPE-19 cells have good in vivo device
viability. ARPE-19 cells can deliver an efficacious quantity of growth
factor. ARPE-19 cells elicit a negligible host immune reaction. Moreover,
ARPE-19 cells are non-tumorigenic.
Claim 1 of 14 Claims